



Polio Publications

1. Badizadegan ND, Wassilak SGF, Estívariz CF, Wiesen E, Burns CC, Bolu O, Thompson KM. Increasing population immunity prior to globally-coordinated cessation of bivalent oral poliovirus vaccine (bOPV). *Pathogens* 2024; 13(9): 804. doi:10.3390/pathogens13090804. <https://www.mdpi.com/2076-0817/13/9/804>. Epub 20240916.
2. Thompson KM, Badizadegan K. Review of Poliovirus Transmission and Economic Modeling to Support Global Polio Eradication: 2020–2024. *Pathogens* 2024; 13(6): 435. doi:10.3390/pathogens13060435. <https://www.mdpi.com/2076-0817/13/6/435>. Epub 20240522.
3. Shattock AJ, Johnson HC, Sim SY, Carter A, Lambach P, Hutubessy RCW, Thompson KM, Badizadegan K, Lambert B, Ferrari MJ, Jit M, Fu H, Silal SP, Hounsell RA, White RG, Mosser JF, Gaythorpe KAM, Trotter CL, Lindstrand A, O'Brien KL, Bar-Zeev N. Contribution of vaccination to improved survival and health: Modelling 50 years of the Expanded Programme on Immunization. *Lancet* 2024; 403(10441): 2307-16. doi:10.1016/S0140-6736(24)00850-X. <https://www.ncbi.nlm.nih.gov/pubmed/38705159>. Epub: 20240502.
4. Thompson KM, Badizadegan K. Evolution of global polio eradication strategies: targets, vaccines, and supplemental immunization activities (SIAs). *Expert Rev Vaccines* 2024; 23(1): 597-613. doi:10.1080/14760584.2024.2361060. <https://www.ncbi.nlm.nih.gov/pubmed/38813792>. Epub: 20240607.
5. Kalkowska DA, Badizadegan K, Routh JA, Burns CC, Rosenberg ES, Brenner IR, Zucker JR, Langdon-Embry M, Thompson KM. Modeling undetected poliovirus circulation following the 2022 outbreak in the United States. *Expert Rev Vaccines* 2024; 23(1): 186-95. doi:10.1080/14760584.2023.2299401. <https://www.ncbi.nlm.nih.gov/pubmed/38164695>. Epub: 20240104.
6. Kalkowska DA, Wassilak SGF, Wiesen E, Burns CC, Pallansch MA, Badizadegan K, Thompson KM. Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences. *Risk Anal* 2024; 44(2): 366-78. doi:10.1111/risa.14158. <https://www.ncbi.nlm.nih.gov/pubmed/37344934>. Epub: 20230621.
7. Kalkowska DA, Wiesen E, Wassilak SGF, Burns CC, Pallansch MA, Badizadegan K, Thompson KM. Worst-case scenarios: Modeling uncontrolled type 2 polio transmission. *Risk Anal* 2024; 44(2): 379-89. doi:10.1111/risa.14159. <https://www.ncbi.nlm.nih.gov/pubmed/37344376>. Epub: 20230621.
8. Shattock AJ, Johnson HC, Sim SY, Carter A, Lambach P, Hutubessy RCW, Thompson KM, Badizadegan K, Lambert B, Ferrari MJ, Jit M, Fu H, Silal SP, Hounsell RA, White RG, Mosser JF, Gaythorpe KAM, Trotter CL, Lindstrand A, O'Brien KL, Bar-Zeev N. Contribution of vaccination to improved survival and health: modelling 50 years of the Expanded Programme on Immunization. *Lancet* 2024. doi:10.1016/S0140-6736(24)00850-X. <https://www.ncbi.nlm.nih.gov/pubmed/38705159>. Epub: 20240502.
9. Thompson KM. Excess vaccine-preventable disease mortality due to COVID-19. *Lancet Glob Health* 2024; 12(4): e531-e2. doi:10.1016/S2214-109X(24)00046-9. [https://www.thelancet.com/journals/langlo/article/PIIS2214-109X\(24\)00046-9/fulltext](https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(24)00046-9/fulltext). Epub: April 2024.
10. Thompson KM, Kalkowska DA, Kidd SE, Burns CC, Badizadegan K. Trade-offs of different poliovirus vaccine options for outbreak response in the United States and other countries that only use inactivated poliovirus vaccine (IPV) in routine immunization. *Vaccine* 2024; 42(4): 819-27. doi:10.1016/j.vaccine.2023.12.081. <https://www.ncbi.nlm.nih.gov/pubmed/38218668>. Epub: 20240112.
11. Thompson KM, Kalkowska DA, Routh JA, Brenner IR, Rosenberg ES, Zucker JR, Langdon-Embry M, Sugerman DE, Burns CC, Badizadegan K. Modeling poliovirus transmission and responses in New York State. *J Infect Dis* 2023; doi:10.1093/infdis/jiad355. <https://www.ncbi.nlm.nih.gov/pubmed/37596838>. Epub: 20230819.
12. Thompson KM, Kalkowska DA, Badizadegan K. Oral polio vaccine stockpile modeling: insights from recent experience. *Expert Rev Vaccines* 2023; 22(1): 813-25. doi:10.1080/14760584.2023.2263096. <https://www.ncbi.nlm.nih.gov/pubmed/37747090>. Epub: 20230929.
13. Badizadegan K, Kalkowska DA, Thompson KM. Health economic analysis of antiviral drugs in the global polio eradication endgame. *Med Decis Making* 2023; 272989x231191127. doi:10.1177/0272989x231191127. <https://pubmed.ncbi.nlm.nih.gov/37577803/>. Epub: 20230814.



14. Thompson KM. Polio endgame complexity: updating expectations for nOPV2. *Lancet Infect Dis* 2023. doi:10.1016/S1473-3099(23)00133-0. <https://www.ncbi.nlm.nih.gov/pubmed/37178705>. Epub: 20230510.
15. Thompson KM, Kalkowska DA, Badizadegan K. Looking back at prospective modeling of outbreak response strategies for managing global type 2 oral poliovirus vaccine (OPV2) cessation. *Front Public Health* 2023; 11. doi:10.3389/fpubh.2023.1098419. <https://www.frontiersin.org/articles/10.3389/fpubh.2023.1098419>. Epub: 20230324.
16. Thompson KM, Luring AS, Pollard AJ, Andino R, Bandyopadhyay AS, Berkley S, Bhutta ZA, Routh J, Benn CS. Polio eradication: Addressing the hurdles on the last mile. *Cell* 2023; 186(1): 1-4. doi:10.1016/j.cell.2022.12.021. <https://www.ncbi.nlm.nih.gov/pubmed/36608647>. Epub: 20230105.
17. Kalkowska DA, Wassilak SGF, Wiesen E, Estivariz CF, Burns CC, Badizadegan K, Thompson KM. Complexity of options related to restarting oral poliovirus vaccine (OPV) in national immunization programs after OPV cessation [version 1; peer review: 1 approved]. *Gates Open Res* 2023. <https://gatesopenresearch.org/articles/7-55>. Epub: 20230417.
18. Thompson KM. Effectiveness of a new vaccine for outbreak response and the increasingly complicated polio endgame. *Lancet Glob Health* 2022; 10(12): e1697-e8. doi:10.1016/S2214-109X(22)00452-1. <https://www.ncbi.nlm.nih.gov/pubmed/36400075> [https://www.thelancet.com/pdfs/journals/langlo/PIIS2214-109X\(22\)00452-1.pdf](https://www.thelancet.com/pdfs/journals/langlo/PIIS2214-109X(22)00452-1.pdf).
19. Kalkowska DA, Wassilak SGF, Pallansch MA, Burns CC, Wiesen E, Durry E, Badizadegan K, Thompson KM. Outbreak response strategies with type 2-containing oral poliovirus vaccines. *Vaccine* 2023. 41 Suppl 1:A142-A52. doi:10.1016/j.vaccine.2022.10.060. <https://www.ncbi.nlm.nih.gov/pubmed/36402659>. Epub 2022 11 16.
20. Thompson KM, Kalkowska DA, Badizadegan K. Health economic analysis of vaccine options for the polio eradication endgame: 2022-2036. *Expert Rev Vaccines* 2022. doi:10.1080/14760584.2022.2128108. <https://www.ncbi.nlm.nih.gov/pubmed/36154436>. Epub 2022 09 26.
21. Badizadegan K, Kalkowska DA, Thompson KM. Polio by the Numbers – A Global Perspective. *J Infect Dis* 2022. <https://doi.org/10.1093/infdis/jiac130>. Epub 2022/04/14.
22. Kalkowska DA, Badizadegan K, Thompson KM. Modeling undetected live type 1 wild poliovirus circulation after apparent interruption of transmission: Pakistan and Afghanistan. *Risk Anal.* 2002. doi:10.1111/risa.13982. <https://pubmed.ncbi.nlm.nih.gov/35739067/>. Epub 2022 Jun 23.
23. Kalkowska DA, Badizadegan K, Thompson KM. Modeling scenarios for ending poliovirus transmission in Pakistan and Afghanistan. *Risk Anal.* 2022. doi:10.1111/risa.13983. <https://pubmed.ncbi.nlm.nih.gov/35739080/>. Epub 23 June 2022.
24. Thompson K, Kalkowska D, Badizadegan K. Polio health economics: assessing the benefits and costs of polio, non-polio, and integrated activities of the Global Polio Eradication Initiative. *Gates Open Research* 2022; 6(5). doi:10.12688/gatesopenres.13524.1. <https://gatesopenresearch.org/articles/6-5/v1>. [version 1; peer review: 2 approved]
25. Thompson KM. Polio eradication: what kind of world do we want? *Lancet Infect Dis* 2022; 22(2): 161-3. doi:10.1016/S1473-3099(21)00458-8. [https://www.thelancet.com/journals/laninf/article/PIIS1473-3099\(21\)00458-8/fulltext](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00458-8/fulltext). Epub 20211011.
26. Thompson KM, Badizadegan K. Health economic analyses of secondary vaccine effects: a systematic review and policy insights. *Expert Rev Vaccines* 2022: 1-16. doi:10.1080/14760584.2022.2017287. <https://www.tandfonline.com/doi/full/10.1080/14760584.2022.2017287>. Epub 20220112.
27. Kalkowska DA, Pallansch MA, Cochi SL, Thompson KM. Modeling poliovirus surveillance and immunization campaign quality monitoring costs for Pakistan and Afghanistan for 2019-2023. *Open Forum Infect Dis* 2021. doi:10.1093/ofid/ofab264. <https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofab264/6282445>. Epub 2021/05/23.
28. Kalkowska DA, Pallansch MA, Wassilak SGF, Cochi SL, Thompson KM. Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response. *Vaccine* 2023. 41 Suppl 1:A136-A41. doi:10.1016/j.vaccine.2021.04.061. <https://www.sciencedirect.com/science/article/pii/S0264410X21005430>. Epub 2021/05/14.
29. Kalkowska DA, Voorman A, Pallansch MA, Wassilak SGF, Cochi SL, Badizadegan K, Thompson KM. The impact of disruptions caused by the COVID-19 pandemic on global polio eradication. *Vaccine* 2023. 41 Suppl 1.



- A12-A8. doi:10.1016/j.vaccine.2021.04.026.
<https://www.sciencedirect.com/science/article/pii/S0264410X21004734>. Epub 2021/04/27.
30. Kalkowska DA, Pallansch MA, Cochi SL, Thompson KM. Updated characterization of poliovirus transmission in Pakistan and Afghanistan and the impacts of different outbreak response vaccine options. *J Infect Dis* 2021. doi:10.1093/infdis/jiab160. <https://www.ncbi.nlm.nih.gov/pubmed/33885734>. Epub 2021/04/23.
31. Thompson KM, Kalkowska DA, Badizadegan K. Hypothetical emergence of poliovirus in 2020: Part 1. Consequences of policy decisions to respond using nonpharmaceutical interventions. *Expert Rev Vaccines* 2021. doi:10.1080/14760584.2021.1891888. <https://www.ncbi.nlm.nih.gov/pubmed/33624568>. Epub 2021/02/25.
32. Thompson KM, Kalkowska DA, Badizadegan K. Hypothetical emergence of poliovirus in 2020: Part 2. Exploration of the potential role of vaccines in control and eradication. *Expert Rev Vaccines* 2021. doi:10.1080/14760584.2021.1891889. <https://www.ncbi.nlm.nih.gov/pubmed/33599178>. Epub 2021/02/19.
33. Thompson KM. Modeling and Managing Poliovirus Risks: We are Where we are.... *Risk Analysis* 2021; 41(2): 223-8. doi:10.1111/risa.13668. <https://pubmed.ncbi.nlm.nih.gov/33590520/>. Epub 2021/2/5.
34. Kalkowska DA, Thompson KM. Health and Economic Outcomes Associated with Polio Vaccine Policy Options: 2019–2029. *Risk Analysis* 2021; 41(2): 364-75. doi:10.1111/risa.13664. <https://pubmed.ncbi.nlm.nih.gov/33590519/>. Epub. 2021/2/5.
35. Thompson KM, Kalkowska DA. An Updated Economic Analysis of the Global Polio Eradication Initiative. *Risk Analysis* 2021; 41(2): 393-406. doi:10.1111/risa.13665. <https://pubmed.ncbi.nlm.nih.gov/33590521/>. Epub 2021/2/5.
36. Thompson KM, Kalkowska DA, Badizadegan K. A Health Economic Analysis for Oral Poliovirus Vaccine to Prevent COVID-19 in the United States. *Risk Anal* 2021; 41(2): 376-86. doi:10.1111/risa.13614. <https://www.ncbi.nlm.nih.gov/pubmed/33084153>. Epub 2020/10/22.
37. Kalkowska DA, Pallansch MA, Wilkinson A, Bandyopadhyay AS, Konopka-Anstadt JL, Burns CC, Oberste MS, Wassilak SGF, Badizadegan K, Thompson KM. Updated Characterization of Outbreak Response Strategies for 2019-2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain. *Risk Anal* 2021; 41(2): 329-48. doi:10.1111/risa.13622. <https://www.ncbi.nlm.nih.gov/pubmed/33174263>. Epub 2020/11/12.
38. Thompson KM, Kalkowska DA, Badizadegan K. No Role for Reintroducing OPV into the United States with Respect to Controlling COVID-19 [Response to the letter to the Editor by Chumakov et al.]. *Risk Anal* 2021; 41(2): 389-92. doi:10.1111/risa.13671. <https://www.ncbi.nlm.nih.gov/pubmed/33590518>. Epub 2021/02/17.
39. Thompson KM. Poliovirus vaccine options: another step forward. *Lancet* 2021; 397(10268): 2-3. doi:10.1016/S0140-6736(20)32629-5. <https://www.ncbi.nlm.nih.gov/pubmed/33308426>. Epub 2020/12/15.
40. Kalkowska DA, Pallansch MA, Cochi SL, Kovacs SD, Wassilak SGF, Thompson KM. Updated Characterization of Post-OPV Cessation Risks: Lessons from 2019 Serotype 2 Outbreaks and Implications for the Probability of OPV Restart. *Risk Anal* 2020. doi:10.1111/risa.13555. <https://www.ncbi.nlm.nih.gov/pubmed/32632925>. Epub 2020/07/08.
41. Kalkowska DA, Thompson KM. Expected Implications of Globally Coordinated Cessation of Serotype 3 Oral Poliovirus Vaccine (OPV) Before Serotype 1 OPV. *Risk Anal* 2020. doi:10.1111/risa.13590. <https://pubmed.ncbi.nlm.nih.gov/32936466/>. Epub 2020/09/17.
42. Thompson KM, Kalkowska DA. Potential Future Use, Costs, and Value of Poliovirus Vaccines. *Risk Anal* 2020. doi:10.1111/risa.13557. <https://www.ncbi.nlm.nih.gov/pubmed/32645244>. Epub 2020/07/10.
43. Thompson KM, Kalkowska DA. Review of poliovirus modeling performed from 2000 to 2019 to support global polio eradication. *Expert Review of Vaccines* 2020: 1-25. doi:10.1080/14760584.2020.1791093. <https://doi.org/10.1080/14760584.2020.1791093>. Epub 2020/08/01.
44. Thompson KM, Kalkowska DA. Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame. *Risk Anal* 2020. doi:10.1111/risa.13484. <https://pubmed.ncbi.nlm.nih.gov/32339327/>. Epub 2020/04/28.
45. Kalkowska DA, Thompson KM. Modeling Undetected Live Poliovirus Circulation After Apparent Interruption of Transmission: Borno and Yobe in Northeast Nigeria. *Risk Anal* 2020. doi:10.1111/risa.13486. <https://pubmed.ncbi.nlm.nih.gov/32348634/>. Epub 2020/04/30.



46. Kalkowska DA, Franka R, Higgins J, Kovacs SD, Forbi JC, Wassilak SGF, Pallansch MA, Thompson KM. Modeling Poliovirus Transmission in Borno and Yobe, Northeast Nigeria. *Risk Anal* 2020. doi:10.1111/risa.13485. <https://pubmed.ncbi.nlm.nih.gov/32348621/>. Epub 2020/04/30.
47. Kalkowska DA, Thompson KM. Insights from modeling preventive supplemental immunization activities as a strategy to eliminate wild poliovirus transmission in Pakistan and Afghanistan. *Risk Anal* 2020. doi:10.1111/risa.13471. <https://pubmed.ncbi.nlm.nih.gov/32144841/>. Epub 2020 Mar 6.
48. Badizadegan K, Goodson JL, Rota PA, Thompson KM. The potential role of using vaccine patches to induce immunity: platform and pathways to innovation and commercialization. *Expert Rev Vaccines* 2020; 19(2): 175-94. doi:10.1080/14760584.2020.1732215. <https://www.ncbi.nlm.nih.gov/pubmed/32182145>. Epub 2020 Mar 17.
49. Kalkowska DA, Pallansch MA, Wassilak SG, Cochi SL, Thompson KM. Global transmission of live polioviruses: Updated dynamic modeling of the polio endgame. *Risk Anal* 2020. doi: 10.1111/risa.13447. <https://www.onlinelibrary.wiley.com/doi/10.1111/risa.13447>. Epub 2020 Jan 20.
50. Thompson KM, Kalkowska DA. Logistical challenges and assumptions for modeling the failure of global cessation of oral poliovirus vaccine (OPV). *Expert Rev Vaccines* 2019; 18(7): 725-36. doi:10.1080/14760584.2019.1635463. <https://www.ncbi.nlm.nih.gov/pubmed/31248293>
51. Thompson KM. Polio endgame options: will we have the vaccines needed? *Lancet* 2019; 394(10193): 99-100. doi:10.1016/S0140-6736(19)31294-2. <https://www.ncbi.nlm.nih.gov/pubmed/31174833>
52. Kalkowska DA, Pallansch MA, Thompson KM. Updated modelling of the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus (iVDPV) excretors. *Epidemiol Infect* 2019; 147: e295. doi:10.1017/s095026881900181x. <https://www.ncbi.nlm.nih.gov/pubmed/31647050>
53. Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. Environmental surveillance system characteristics and impacts on confidence about no undetected serotype 1 wild poliovirus circulation. *Risk Anal* 2019; 39(2): 414-25. doi:10.1111/risa.13193. <https://www.ncbi.nlm.nih.gov/pubmed/30239023>
54. Kalkowska DA, Duintjer Tebbens RJ, Pallansch MA, Thompson KM. Modeling undetected live poliovirus circulation after apparent interruption of transmission: Pakistan and Afghanistan. *Risk Anal* 2019; 39(2): 402-13. doi:10.1111/risa.13214. <https://www.ncbi.nlm.nih.gov/pubmed/30296340>
55. Duintjer Tebbens RJ, Thompson KM. Evaluation of proactive and reactive strategies for polio eradication activities in Pakistan and Afghanistan. *Risk Anal* 2019; 39(2): 389-401. doi:10.1111/risa.13194. <https://www.ncbi.nlm.nih.gov/pubmed/30239026>
56. Duintjer Tebbens RJ, Kalkowska DA, Thompson KM. Global certification of wild poliovirus eradication: insights from modelling hard-to-reach subpopulations and confidence about the absence of transmission. *BMJ Open* 2019; 9(1): e023938. doi:10.1136/bmjopen-2018-023938. <https://www.ncbi.nlm.nih.gov/pubmed/30647038>
57. Duintjer Tebbens RJ, Diop OM, Pallansch MA, Oberste MS, Thompson KM. Characterising the costs of the global polio laboratory network: a survey-based analysis. *BMJ Open* 2019; 9(1): e023290. doi:10.1136/bmjopen-2018-023290. <https://www.ncbi.nlm.nih.gov/pubmed/30670511>
58. Tebbens RJD, Kalkowska DA, Thompson KM. Poliovirus containment risks and their management. *Future Virology* 2018; 13(9): 617-28. doi:10.2217/fvl-2018-0079. <https://www.futuremedicine.com/doi/abs/10.2217/fvl-2018-0079>
59. Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. Another look at silent circulation of poliovirus in small populations. *Infect Dis Model* 2018; 3: 107-17. doi:10.1016/j.idm.2018.06.001. <https://www.ncbi.nlm.nih.gov/pubmed/30839913>
60. Duintjer Tebbens RJ, Thompson KM. Using integrated modeling to support the global eradication of vaccine-preventable diseases. *System Dynamics Review* 2018; 34(1-2): 78-120. doi:10.1002/sdr.1589. <https://onlinelibrary.wiley.com/doi/abs/10.1002/sdr.1589>
61. Duintjer Tebbens RJ, Thompson KM. Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine. *Expert Rev Vaccines* 2018; 17(8): 739-51. doi:10.1080/14760584.2018.1506333. <https://www.ncbi.nlm.nih.gov/pubmed/30056767>



62. Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Ehrhardt DT, Farag NH, Hadler SC, Hampton LM, Martinez M, Wassilak SGF, Thompson KM. Modeling poliovirus transmission in Pakistan and Afghanistan to inform vaccination strategies in undervaccinated subpopulations. *Risk Anal* 2018; 38(8): 1701-17. doi:10.1111/risa.12962. <https://www.ncbi.nlm.nih.gov/pubmed/29314143>
63. Duintjer Tebbens RJ, Hampton LM, Thompson KM. Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use. *BMC Infect Dis* 2018; 18(1): 165. doi:10.1186/s12879-018-3074-0. <https://www.ncbi.nlm.nih.gov/pubmed/29631539>
64. Thompson KM, Tebbens RJD. How should we prepare for an outbreak of reintroduced live polioviruses? *Future Virology* 2017; 12(2): 41-4. doi:10.2217/fvl-2016-0131. <https://www.futuremedicine.com/doi/abs/10.2217/fvl-2016-0131>
65. Thompson KM, Duintjer Tebbens RJ. Lessons from globally coordinated cessation of serotype 2 oral poliovirus vaccine for the remaining serotypes. *J Infect Dis* 2017; 216(suppl_1): S168-S75. doi:10.1093/infdis/jix128. <https://www.ncbi.nlm.nih.gov/pubmed/28838198>
66. Thompson KM, Duintjer Tebbens RJ. Lessons from the polio endgame: overcoming the failure to vaccinate and the role of subpopulations in maintaining transmission. *J Infect Dis* 2017; 216(suppl_1): S176-S82. doi:10.1093/infdis/jix108. <https://www.ncbi.nlm.nih.gov/pubmed/28838194>
67. Duintjer Tebbens RJ, Zimmermann M, Pallansch MA, Thompson KM. Insights from a systematic search for information on designs, costs, and effectiveness of poliovirus environmental surveillance systems. *Food Environ Virol* 2017; 9(4): 361-82. doi:10.1007/s12560-017-9314-4. <https://www.ncbi.nlm.nih.gov/pubmed/28687986>
68. Duintjer Tebbens RJ, Thompson KM. Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential oral poliovirus vaccine cessation risk management strategy. *Epidemiol Infect* 2017; 145(2): 217-26. doi:10.1017/S0950268816002302. <https://www.ncbi.nlm.nih.gov/pubmed/27760579>
69. Duintjer Tebbens RJ, Thompson KM. Costs and benefits of including inactivated in addition to oral poliovirus vaccine in outbreak response after cessation of oral poliovirus vaccine use. *MDM Policy Pract* 2017; 2(1): 2381468317697002. doi:10.1177/2381468317697002. <https://www.ncbi.nlm.nih.gov/pubmed/30288417>
70. Duintjer Tebbens RJ, Thompson KM. Poliovirus vaccination during the endgame: insights from integrated modeling. *Expert Rev Vaccines* 2017; 16(6): 577-86. doi:10.1080/14760584.2017.1322514. <https://www.ncbi.nlm.nih.gov/pubmed/28437234>
71. Duintjer Tebbens RJ, Thompson KM. Modeling the costs and benefits of temporary recommendations for poliovirus exporting countries to vaccinate international travelers. *Vaccine* 2017; 35(31): 3823-33. doi:10.1016/j.vaccine.2017.05.090. <https://www.ncbi.nlm.nih.gov/pubmed/28606811>
72. Thompson KM, Logan GE, Florida SRT. Characterization of heterogeneity in childhood immunization coverage in central Florida using immunization registry data. *Risk Anal* 2016; 36(7): 1418-26. doi:10.1111/risa.12424. <https://www.ncbi.nlm.nih.gov/pubmed/26033542>
73. Tebbens RJD, Hampton LM, Wassilak SGF, Pallansch MA, Cochi SL, Thompson KM. Maintenance and intensification of bivalent oral poliovirus vaccine use prior to its coordinated global cessation. *J Vaccines Vaccin* 2016; 7(5). doi:10.4172/2157-7560.1000340. <https://www.ncbi.nlm.nih.gov/pubmed/28690915>
74. Duintjer Tebbens RJ, Thompson KM. Uncertainty and sensitivity analysis of cost assumptions for global long-term poliovirus risk management *J Vaccines Vaccin* 2016; 7(5): 1000339. doi:10.4172/2157-7560.1000339. <https://www.longdom.org/open-access/uncertainty-and-sensitivity-analysis-of-cost-assumptions-for-global-longtermpoliovirus-risk-management-2157-7560-1000339.pdf>
75. Duintjer Tebbens RJ, Thompson KM. The potential benefits of a new poliovirus vaccine for long-term poliovirus risk management. *Future Microbiol* 2016; 11: 1549-61. doi:10.2217/fmb-2016-0126. <https://www.ncbi.nlm.nih.gov/pubmed/27831742>
76. Duintjer Tebbens RJ, Pallansch MA, Wassilak SG, Cochi SL, Thompson KM. Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame. *BMC Infect Dis* 2016; 16: 137. doi:10.1186/s12879-016-1465-7. <https://www.ncbi.nlm.nih.gov/pubmed/27009272>



77. Duintjer Tebbens RJ, Hampton LM, Thompson KM. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation. *BMC Infect Dis* 2016; 16: 231. doi:10.1186/s12879-016-1536-9. <https://www.ncbi.nlm.nih.gov/pubmed/27230071>
78. Duintjer Tebbens RJ, Hampton LM, Thompson KM. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use. *BMC Infect Dis* 2016; 16: 237. doi:10.1186/s12879-016-1537-8. <https://www.ncbi.nlm.nih.gov/pubmed/27246198>
79. Thompson KM, Kalkowska DA, Duintjer Tebbens RJ. Managing population immunity to reduce or eliminate the risks of circulation following the importation of polioviruses. *Vaccine* 2015; 33(13): 1568-77. doi:10.1016/j.vaccine.2015.02.013. <https://www.ncbi.nlm.nih.gov/pubmed/25701673>
80. Thompson KM, Duintjer Tebbens RJ, Pallansch MA, Wassilak SG, Cochi SL. Polio eradicators use integrated analytical models to make better decisions. *INFORMS Journal on Applied Analytics* 2015; 45(1): 5-25. doi:10.1287/inte.2014.0769. <https://pubsonline.informs.org/doi/abs/10.1287/inte.2014.0769>
81. Thompson KM, Duintjer Tebbens RJ. Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes. *BMC Infect Dis* 2015; 15: 374. doi:10.1186/s12879-015-1113-7. <https://www.ncbi.nlm.nih.gov/pubmed/26381878>
82. Thompson KM, Duintjer Tebbens RJ. The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission. *BMC Infect Dis* 2015; 15: 376. doi:10.1186/s12879-015-1116-4. <https://www.ncbi.nlm.nih.gov/pubmed/26382234>
83. Thompson KM. Good news for billions of children who will receive IPV. *Lancet Infect Dis* 2015; 15(10): 1120-2. doi:10.1016/S1473-3099(15)00099-7. <https://www.ncbi.nlm.nih.gov/pubmed/26289957>
84. Kalkowska DA, Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SG, Thompson KM. Modeling undetected live poliovirus circulation after apparent interruption of transmission: implications for surveillance and vaccination. *BMC Infect Dis* 2015; 15: 66. doi:10.1186/s12879-015-0791-5. <https://www.ncbi.nlm.nih.gov/pubmed/25886823>
85. Kalkowska DA, Duintjer Tebbens RJ, Grotto I, Shulman LM, Anis E, Wassilak SG, Pallansch MA, Thompson KM. Modeling options to manage type 1 wild poliovirus imported into Israel in 2013. *J Infect Dis* 2015; 211(11): 1800-12. doi:10.1093/infdis/jiu674. <https://www.ncbi.nlm.nih.gov/pubmed/25505296>
86. Duintjer Tebbens RJ, Thompson KM. Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs. *BMC Infect Dis* 2015; 15: 390. doi:10.1186/s12879-015-1114-6. <https://www.ncbi.nlm.nih.gov/pubmed/26404780>
87. Duintjer Tebbens RJ, Pallansch MA, Wassilak SG, Cochi SL, Thompson KM. Combinations of quality and frequency of immunization activities to stop and prevent poliovirus transmission in the high-risk area of northwest Nigeria. *PLoS One* 2015; 10(6): e0130123. doi:10.1371/journal.pone.0130123. <https://www.ncbi.nlm.nih.gov/pubmed/26068928>
88. Duintjer Tebbens RJ, Pallansch MA, Thompson KM. Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs. *BMC Infect Dis* 2015; 15: 379. doi:10.1186/s12879-015-1115-5. <https://www.ncbi.nlm.nih.gov/pubmed/26382043>
89. Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SG, Thompson KM. An economic analysis of poliovirus risk management policy options for 2013-2052. *BMC Infect Dis* 2015; 15: 389. doi:10.1186/s12879-015-1112-8. <https://www.ncbi.nlm.nih.gov/pubmed/26404632>
90. Thompson KM, Duintjer Tebbens RJ. Modeling the dynamics of oral poliovirus vaccine cessation. *J Infect Dis* 2014; 210 Suppl 1: S475-84. doi:10.1093/infdis/jit845. <https://www.ncbi.nlm.nih.gov/pubmed/25316870>
91. Thompson KM, Duintjer Tebbens RJ. National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradication. *Expert Rev Vaccines* 2014; 13(2): 221-34. doi:10.1586/14760584.2014.864563. <https://www.ncbi.nlm.nih.gov/pubmed/24308581>
92. Thompson KM. Polio endgame management: focusing on performance with or without inactivated poliovirus vaccine. *Lancet* 2014; 384(9953): 1480-2. doi:10.1016/S0140-6736(14)60983-1. <https://www.ncbi.nlm.nih.gov/pubmed/25018123>
93. Kisjes KH, Duintjer Tebbens RJ, Wallace GS, Pallansch MA, Cochi SL, Wassilak SG, Thompson KM. Individual-based modeling of potential poliovirus transmission in connected religious communities in North America



- with low uptake of vaccination. *J Infect Dis* 2014; 210 Suppl 1: S424-33. doi:10.1093/infdis/jit843. <https://www.ncbi.nlm.nih.gov/pubmed/25316864>
94. Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. Modeling strategies to increase population immunity and prevent poliovirus transmission in 2 high-risk areas in northern India. *J Infect Dis* 2014; 210 Suppl 1: S398-411. doi:10.1093/infdis/jit844. <https://www.ncbi.nlm.nih.gov/pubmed/25316861>
95. Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of northwest Nigeria. *J Infect Dis* 2014; 210 Suppl 1: S412-23. doi:10.1093/infdis/jit834. <https://www.ncbi.nlm.nih.gov/pubmed/25316863>
96. Duintjer Tebbens RJ, Thompson KM. Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation. *J Infect Dis* 2014; 210 Suppl 1: S485-97. doi:10.1093/infdis/jit838. <https://www.ncbi.nlm.nih.gov/pubmed/25316871>
97. Duintjer Tebbens RJ, Kalkowska DA, Wassilak SG, Pallansch MA, Cochi SL, Thompson KM. The potential impact of expanding target age groups for polio immunization campaigns. *BMC Infect Dis* 2014; 14: 45. doi:10.1186/1471-2334-14-45. <https://www.ncbi.nlm.nih.gov/pubmed/24472313>
98. Thompson KM, Pallansch MA, Tebbens RJ, Wassilak SG, Cochi SL. Modeling population immunity to support efforts to end the transmission of live polioviruses. *Risk Anal* 2013; 33(4): 647-63. doi:10.1111/j.1539-6924.2012.01891.x. <https://www.ncbi.nlm.nih.gov/pubmed/22985171>
99. Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SG, Kim JH, Cochi SL. Preradication vaccine policy options for poliovirus infection and disease control. *Risk Anal* 2013; 33(4): 516-43. doi:10.1111/risa.12019. <https://www.ncbi.nlm.nih.gov/pubmed/23461599>
100. Thompson KM. Modeling poliovirus risks and the legacy of polio eradication. *Risk Anal* 2013; 33(4): 505-15. doi:10.1111/risa.12030. <https://www.ncbi.nlm.nih.gov/pubmed/23550939>
101. Duintjer Tebbens RJ, Pallansch MA, Kim JH, Burns CC, Kew OM, Oberste MS, Diop OM, Wassilak SG, Cochi SL, Thompson KM. Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs). *Risk Anal* 2013; 33(4): 680-702. doi:10.1111/risa.12022. <https://www.ncbi.nlm.nih.gov/pubmed/23470192>
102. Duintjer Tebbens RJ, Pallansch MA, Kalkowska DA, Wassilak SG, Cochi SL, Thompson KM. Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses. *Risk Anal* 2013; 33(4): 703-49. doi:10.1111/risa.12044. <https://www.ncbi.nlm.nih.gov/pubmed/23521018>
103. Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, Wassilak SG, Cochi SL, Kim JH, Thompson KM. Expert review on poliovirus immunity and transmission. *Risk Anal* 2013; 33(4): 544-605. doi:10.1111/j.1539-6924.2012.01864.x. <https://www.ncbi.nlm.nih.gov/pubmed/22804479>
104. Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, Wassilak SG, Cochi SL, Kim JH, Thompson KM. Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs. *Risk Anal* 2013; 33(4): 606-46. doi:10.1111/risa.12031. <https://www.ncbi.nlm.nih.gov/pubmed/23550968>
105. Thompson KM, Wallace GS, Tebbens RJ, Smith PJ, Barskey AE, Pallansch MA, Gallagher KM, Alexander JP, Armstrong GL, Cochi SL, Wassilak SG. Trends in the risk of U.S. polio outbreaks and poliovirus vaccine availability for response. *Public Health Rep* 2012; 127(1): 23-37. doi:10.1177/003335491212700104. <https://www.ncbi.nlm.nih.gov/pubmed/22298920>
106. Thompson KM, Tebbens RJ. Current polio global eradication and control policy options: perspectives from modeling and prerequisites for oral poliovirus vaccine cessation. *Expert Rev Vaccines* 2012; 11(4): 449-59. doi:10.1586/erv.11.195. <https://www.ncbi.nlm.nih.gov/pubmed/22551030>
107. Thompson KM. The role of risk analysis in polio eradication: modeling possibilities, probabilities and outcomes to inform choices. *Expert Rev Vaccines* 2012; 11(1): 5-7. doi:10.1586/erv.11.163. <https://www.ncbi.nlm.nih.gov/pubmed/22149700>
108. Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. The probability of undetected wild poliovirus circulation after apparent global interruption of transmission. *Am J Epidemiol* 2012; 175(9): 936-49. doi:10.1093/aje/kwr399. <https://www.ncbi.nlm.nih.gov/pubmed/22459121>



109. Thompson KM, Rabinovich R, Conteh L, Emerson CI, Hall BF, Singer PA, Vijayaraghavan M, Walker D. Group report: developing an eradication investment case. In: Cochi SL, Dowdle WR, eds. *Disease Eradication in the 21st Century: Implications for Global Health*. Cambridge, MA: MIT Press; 2011: 133-48.
110. Thompson KM, Duintjer Tebbens RJ. Economic evaluation of the benefits and costs of disease elimination and eradication initiatives. In: Cochi SL, Dowdle WR, eds. *Disease Eradication in the 21st Century: Implications for Global Health*. Cambridge, MA: MIT Press; 2011: 115-30.
111. Rahmandad H, Hu K, Duintjer Tebbens RJ, Thompson KM. Development of an individual-based model for polioviruses: implications of the selection of network type and outcome metrics. *Epidemiol Infect* 2011; 139(6): 836-48. doi:10.1017/S0950268810001676. <https://www.ncbi.nlm.nih.gov/pubmed/20619075>
112. Tebbens RJ, Pallansch MA, Alexander JP, Thompson KM. Optimal vaccine stockpile design for an eradicated disease: application to polio. *Vaccine* 2010; 28(26): 4312-27. doi:10.1016/j.vaccine.2010.04.001. <https://www.ncbi.nlm.nih.gov/pubmed/20430122>
113. Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SG, Linkins J, Sutter RW, Aylward RB, Thompson KM. Economic analysis of the global polio eradication initiative. *Vaccine* 2010; 29(2): 334-43. doi:10.1016/j.vaccine.2010.10.026. <https://www.ncbi.nlm.nih.gov/pubmed/21029809>
114. Thompson KM, Tebbens RJD. Using system dynamics to develop policies that matter: global management of poliomyelitis and beyond. *System Dynamics Review* 2008; 24(4): 433-49. doi:10.1002/sdr.419. <https://onlinelibrary.wiley.com/doi/abs/10.1002/sdr.419>
115. Thompson KM, Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Aylward RB, Watkins M, Gary HE, Jr., Alexander J, Jafari H, Cochi SL. The risks, costs, and benefits of possible future global policies for managing polioviruses. *Am J Public Health* 2008; 98(7): 1322-30. doi:10.2105/AJPH.2007.122192. <https://www.ncbi.nlm.nih.gov/pubmed/18511720>
116. Thompson KM, Duintjer Tebbens RJ. The case for cooperation in managing and maintaining the end of poliomyelitis: stockpile needs and coordinated OPV cessation. *Medscape J Med* 2008; 10(8): 190. <https://www.ncbi.nlm.nih.gov/pubmed/18924642>
117. Duintjer Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Bruce Aylward R, Watkins M, Gary H, Alexander J, Jafari H, Cochi SL, Thompson KM. Uncertainty and sensitivity analyses of a decision analytic model for posteradication polio risk management. *Risk Anal* 2008; 28(4): 855-76. doi:10.1111/j.1539-6924.2008.01078.x. <https://www.ncbi.nlm.nih.gov/pubmed/18627544>
118. Thompson KM, Duintjer Tebbens RJ. Eradication versus control for poliomyelitis: an economic analysis. *Lancet* 2007; 369(9570): 1363-71. doi:10.1016/S0140-6736(07)60532-7. <https://www.ncbi.nlm.nih.gov/pubmed/17448822>
119. Thompson KM. Eradicating polio: the dollars and sense. *MedGenMed* 2007; 9(4): 11. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2234286/>
120. Thompson KM, Tebbens RJ. Retrospective cost-effectiveness analyses for polio vaccination in the United States. *Risk Anal* 2006; 26(6): 1423-40. doi:10.1111/j.1539-6924.2006.00831.x. <https://www.ncbi.nlm.nih.gov/pubmed/17184390>
121. Thompson KM, Duintjer Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Aylward RB, Watkins M, Gary H, Alexander JP, Venczel L, Johnson D, Caceres VM, Sangrujee N, Jafari H, Cochi SL. Development and consideration of global policies for managing the future risks of poliovirus outbreaks: insights and lessons learned through modeling. *Risk Anal* 2006; 26(6): 1571-80. doi:10.1111/j.1539-6924.2006.00841.x. <https://www.ncbi.nlm.nih.gov/pubmed/17184398>
122. Thompson KM, Duintjer Tebbens RJ, Pallansch MA. Evaluation of response scenarios to potential polio outbreaks using mathematical models. *Risk Anal* 2006; 26(6): 1541-56. doi:10.1111/j.1539-6924.2006.00843.x. <https://www.ncbi.nlm.nih.gov/pubmed/17184396>
123. Thompson KM. Poliomyelitis and the role of risk analysis in global infectious disease policy and management. *Risk Anal* 2006; 26(6): 1419-21. doi:10.1111/j.1539-6924.2006.00853.x. <https://www.ncbi.nlm.nih.gov/pubmed/17184389>
124. Tebbens RJ, Sangrujee N, Thompson KM. The costs of future polio risk management policies. *Risk Anal* 2006; 26(6): 1507-31. doi:10.1111/j.1539-6924.2006.00842.x. <https://www.ncbi.nlm.nih.gov/pubmed/17184394>



125. Tebbens RJ, Pallansch MA, Kew OM, Caceres VM, Jafari H, Cochi SL, Sutter RW, Aylward RB, Thompson KM. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. *Risk Anal* 2006; 26(6): 1471-505. doi:10.1111/j.1539-6924.2006.00827.x. <https://www.ncbi.nlm.nih.gov/pubmed/17184393>
126. de Gourville E, Duintjer Tebbens RJ, Sangrujee N, Pallansch MA, Thompson KM. Global surveillance and the value of information: the case of the global polio laboratory network. *Risk Anal* 2006; 26(6): 1557-69. doi:10.1111/j.1539-6924.2006.00845.x. <https://www.ncbi.nlm.nih.gov/pubmed/17184397>
127. Bruce Aylward R, Sutter RW, Cochi SL, Thompson KM, Jafari H, Heymann D. Risk management in a polio-free world. *Risk Anal* 2006; 26(6): 1441-8. doi:10.1111/j.1539-6924.2006.00840.x. <https://www.ncbi.nlm.nih.gov/pubmed/17184391>
128. Duintjer Tebbens RJ, Pallansch MA, Kew OM, Caceres VM, Sutter RW, Thompson KM. A dynamic model of poliomyelitis outbreaks: learning from the past to help inform the future. *Am J Epidemiol* 2005; 162(4): 358-72. doi:10.1093/aje/kwi206. <https://www.ncbi.nlm.nih.gov/pubmed/16014773>
129. Sangrujee N, Duintjer Tebbens RJ, Caceres VM, Thompson KM. Policy decision options during the first 5 years following certification of polio eradication. *MedGenMed* 2003; 5(4): 35. <https://www.ncbi.nlm.nih.gov/pubmed/14745382>